AstraZeneca's Wainua Fails Key Heart Disease Trial, Shares Tumble Down

AstraZeneca's Wainua (eplontersen), developed with U.S. partner Ionis Pharmaceuticals, failed to meet the primary efficacy endpoint of the Phase III CARDIO-TTRansform trial, missing a statistically significant reduction in the composite of cardiovascular mortality and recurrent cardiovascular events over 140 weeks versus placebo in patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) . AZN shares fell about 9% in early trading on the news, erasing an estimated £19 billion in market value, while Ionis shares dropped roughly 19%.

The result matters because ATTR-CM is a progressive, often fatal buildup of misfolded protein in the heart, and a positive readout could have expanded Wainua beyond its existing approval for polyneuropathy into a much larger cardiac indication. The miss also hands a competitive edge to rival Alnylam Pharmaceuticals, whose approved ATTR-CM therapy Amvuttra now stands as the only silencer-class drug on the market for the condition: Alnylam shares climbed roughly 16% in premarket trading as investors priced in reduced competition.

Investors should watch how AstraZeneca and Ionis respond from here. A prespecified subgroup analysis reportedly showed a nominally significant benefit for patients on Wainua monotherapy versus placebo, and the companies plan to present the full data set at the European Society of Cardiology Congress in August 2026, which could reshape how the market ultimately reads this result. Until then, the trial miss could weigh on sentiment around AstraZeneca's cardiovascular pipeline and may prompt questions about how the company positions Wainua's future development and any label strategy going forward.

Related Stocks

• AZN